PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors.
Staniszewska AD, Armenia J, King M, Michaloglou C, Reddy A, Singh M, San Martin M, Prickett L, Wilson Z, Proia T, Russell D, Thomas M, Delpuech O, O'Connor MJ, Leo E, Angell H, Valge-Archer V.
Staniszewska AD, et al. Among authors: san martin m.
Oncoimmunology. 2022 Jun 18;11(1):2083755. doi: 10.1080/2162402X.2022.2083755. eCollection 2022.
Oncoimmunology. 2022.
PMID: 35756843
Free PMC article.